Optimi Health Corp. OPTH Archives

WednesdayJun 10, 2026 10:32 am

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the completion of its first export of naturally derived psilocybin to the United Kingdom in support of a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5 mg psilocybin capsules manufactured at the company's GMP facility in Princeton, British Columbia. Optimi Health said the capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression and were exported under authorization from Health Canada and the UK Home Office.…

FridayMay 29, 2026 9:10 am

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage psychedelic pharmaceutical manufacturer, welcomed final recommendations from Australia's Therapeutic Goods Administration regarding its Authorized Prescriber scheme for psilocybin and MDMA. The updated framework broadens eligible therapy teams, expands treatment settings beyond hospital environments and supports scaling of psychedelic-assisted therapy across Australia, where authorized psychiatrists can prescribe Optimi's GMP-compliant MDMA for PTSD and psilocybin for treatment-resistant depression. The company said the revised framework could accelerate adoption of psychedelic-assisted therapy by increasing workforce capacity, particularly in…

ThursdayMay 21, 2026 10:45 am

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market, offering 2.4 million common shares at US$6.25 per share for expected gross proceeds of approximately US$15 million, excluding any exercise of the underwriter’s option to purchase up to an additional 360,000 shares. Joseph Gunnar & Co. LLC is acting as sole book-running manager for the offering, with trading on Nasdaq expected to begin May 20, 2026, under the…

Site Search

Company Search

Tag: Optimi Health Corp. OPTH

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes First Psilocybin Export to United Kingdom for Planned Phase 2 Trial

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Highlights Australia Psychedelic Therapy Expansion Following TGA Framework Update

QualityStocksNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Prices $15 Million Public Offering in Connection With Nasdaq Uplisting

Market Basics

Newsletter Publishers

Public Companies